Victoria will undergo brain surgery on Jan. 17 in Houston, but her problems won’t go away with just one operation.

Corcept Therapeutics Incorporated (NASDAQ: CORT) has recently submitted a New Drug Application (NDA) to the U.S. Food and ...

Corcept Therapeutics Inc. (CORT) said that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body ...

Corcept is studying relacorilant in a variety of serious disorders in addition to endogenous hypercortisolism (Cushing’s syndrome), including ovarian, adrenal and prostate cancer. Relacorilant is ...

DEAR JOAN: My daughter has a dog that has been suffering with Cushing’s disease for several years now. She cannot get up on ...

DEAR JOAN: My daughter has a dog that has been suffering with Cushing’s disease for several years now. She cannot get up on ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

In patients with Cushing’s syndrome, hypercortisolemia causes various complications, including cerebrocardiovascular events, infectious diseases, and thromboembolisms, which increase mortality (1–3).

LUBUMBASHI, Democratic Republic of the Congo – The nation's health ministry said Tuesday that a previously unidentified disease circulating in the country's Panzi health zone is a severe form ...

In addition to Cushing's syndrome, relacorilant is being investigated for its potential use in treating various cancers, including ovarian, adrenal and prostate cancer. Corcept holds proprietary ...

US-based biotechnology company Corcept Therapeutics has reported positive long-term outcomes from its Phase III study of relacorilant, a treatment for individuals with endogenous hypercortisolism, ...